Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lorazepam belongs to a group of medicines called benzodiazepines. It works by enhancing the effects of a naturally occurring chemical messenger in the brain called GABA. GABA has a calming effect on nerve activity; lorazepam helps GABA work more effectively by making the chloride channels on nerve cells open more often when GABA is present. The medicine doesn't activate these channels on its own — it needs GABA to be there — but it amplifies GABA's natural calming action. This is how lorazepam produces its effects on anxiety, agitation, and muscle tension.
Lorazepam is prescribed for pre-operative sedation, for calming acute anxiety or agitation, and to control seizures including status epilepticus. Once in the body, it has a half-life of ten to twenty hours, meaning it takes that long for half the dose to be eliminated. Unlike many other benzodiazepines, lorazepam is not broken down by the liver enzymes of the cytochrome P450 system, which means fewer interactions with other medicines that rely on those enzymes.
Common side effects your family member might experience include sedation or drowsiness, unsteadiness when walking, dizziness, nausea, constipation, vomiting, and fatigue. Lorazepam is thought to have a particularly strong effect on memory formation, so marked memory gaps around the time of taking the medicine can occur.
Serious side effects requiring urgent medical attention include respiratory depression, seizures, a severe drop in white blood cells, severe allergic reactions, and suicidal thoughts or actions. Lorazepam should not be used in people with pulmonary insufficiency, sleep apnoea, myasthenia gravis, severe liver disease, or a known hypersensitivity to benzodiazepines.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
“Benzodiazepines presumably exert their effects by binding to specific receptors at several sites within the central nervous system either by potentiating the effects of synaptic or pre-synaptic inhibition mediated by gamma-aminobutyric acid or by directly affecting the action potential generating mechanisms.”
“The elimination half-life is about 12-16 hours when given intramuscularly or intravenously.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lorazepam is a benzodiazepine derivative that enhances GABAergic neurotransmission by increasing the frequency of chloride-channel opening at GABAA receptors in the presence of endogenous GABA. TGA-approved indications include pre-operative medication, premedication for prolonged investigations, treatment of acute anxiety states and acute agitation, and control of status epilepticus in adults, adolescents, and children. The mechanism confers anxiolytic, sedative, anticonvulsant, and amnesic properties; lorazepam is thought to exhibit high affinity for GABA receptors, which may account for its marked amnesic effects.
The elimination half-life is 10–20 hours (12–16 hours when given intramuscularly or intravenously). Lorazepam is not a substrate for cytochrome P450 N-dealkylating enzymes and is not hydroxylated to any significant extent, conferring a relatively low risk of CYP-mediated drug interactions. Common adverse effects include sedation, drowsiness, ataxia, dizziness, nausea, and fatigue. Serious adverse effects include respiratory depression, convulsions or seizures, suicidal ideation or attempt, agranulocytosis, and anaphylactic or anaphylactoid reactions. Contraindications include pulmonary insufficiency, sleep apnoea syndrome, myasthenia gravis, severe hepatic insufficiency, and hypersensitivity to benzodiazepines or excipients.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Lorazepam is not a substrate for N-dealkylating enzymes of the cytochrome P450 system nor is it hydroxylated to any significant extent.”